Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710254 · ClinicalTrials.gov registry record · Phase 2
Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients
A Phase 2 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01710254 is a Phase 2 study that has completed, run by University of Utah. The registered enrollment target is 30 participants.
The verdict
NCT01710254, a Phase 2 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Atrial fibrillation (AF) is growing into an epidemic affecting 1 in 4 adults. There is a need for research to elucidate the prevalence of ischemic cardiomyopathy in patients diagnosed with AF. The objective of this study is to demonstrate the utility of MRI in assessment of coronary artery disease. The specific objective is to demonstrate sensitivity/specificity comparable to that reported in meta-analyses of non-AF patients and adenosine (90% /80%) in an AF population using the time-efficient vasodilator regadenoson that requires only a single intravenous (IV).
Interventions
- DRUG Gadobenate dimeglumine
- DRUG Regadenoson MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710254
The ClinicalTrials.gov registry entry for NCT01710254 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gadobenate dimeglumine is the first listed.
NCT01710254 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710254 about?
NCT01710254 is a clinical study titled "Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients". Atrial fibrillation (AF) is growing into an epidemic affecting 1 in 4 adults. There is a need for research to elucidate the prevalence of ischemic cardiomyopathy in patients diagnosed with AF. The objective of this study is to demonstrate the utility of MRI in assessment of coronary artery disease. ...
What is the current status of trial NCT01710254?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01710254?
The interventions under investigation include: Gadobenate dimeglumine (DRUG), Regadenoson MRI (DRUG).
Who is sponsoring clinical trial NCT01710254?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.